JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

14.06 -9.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.91

Max

15.82

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.5M -74M
Gewinnspanne	-1,582.642
Angestellte	205
EBITDA	1.7M -72M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+49.03% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	583M 2.3B
Vorheriger Eröffnungskurs	23.29
Vorheriger Schlusskurs	14.06

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Nov. 2025, 21:44 UTC

Ergebnisse

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3. Nov. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3. Nov. 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3. Nov. 2025, 23:28 UTC

Ergebnisse

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3. Nov. 2025, 23:24 UTC

Ergebnisse

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. Nov. 2025, 23:14 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

3. Nov. 2025, 23:14 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3. Nov. 2025, 23:12 UTC

Ergebnisse

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. Nov. 2025, 23:09 UTC

Ergebnisse

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3. Nov. 2025, 23:09 UTC

Ergebnisse

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3. Nov. 2025, 23:09 UTC

Ergebnisse

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3. Nov. 2025, 23:06 UTC

Market Talk

Ergebnisse

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3. Nov. 2025, 22:36 UTC

Market Talk

Ergebnisse

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3. Nov. 2025, 22:31 UTC

Ergebnisse

Franco-Nevada 3Q EPS $1.49 >FNV

3. Nov. 2025, 22:31 UTC

Ergebnisse

Franco-Nevada 3Q Rev $487.7M >FNV

3. Nov. 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3. Nov. 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Starbucks Agrees to Sell Stake in China Business -- WSJ

3. Nov. 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3. Nov. 2025, 21:54 UTC

Market Talk

Ergebnisse

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3. Nov. 2025, 21:54 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

3. Nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Nov. 2025, 21:49 UTC

Ergebnisse

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3. Nov. 2025, 21:40 UTC

Ergebnisse

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3. Nov. 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3. Nov. 2025, 21:19 UTC

Ergebnisse

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3. Nov. 2025, 21:11 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3. Nov. 2025, 21:11 UTC

Ergebnisse

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3. Nov. 2025, 21:07 UTC

Ergebnisse

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3. Nov. 2025, 21:05 UTC

Ergebnisse

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3. Nov. 2025, 21:05 UTC

Ergebnisse

Palantir Technologies 3Q Net $475.6M >PLTR

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

49.03% Vorteil

12-Monats-Prognose

Durchschnitt 23.1 USD 49.03%

Hoch 44 USD

Tief 11 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.